Ibex Medical Analytics

Company Overview

Snapshot

Founded in January 2016 by Joseph (Yossi) Mossel and Chaim Linhart, Ibex Medical Analytics operates with 51–200 employees. The company has raised $116.6 million across 5 funding rounds from 10 investors, with 83North leading a round in September 2023. In February 2025, the company announced a new executive appointment following a significant funding raise.

Business overview

Ibex Medical Analytics develops clinical-grade artificial intelligence solutions for cancer diagnostics. Its core product, the Galen platform, utilizes algorithms to analyze images, detect and grade cancer in biopsies, and identify other clinically important findings. This technology aims to reduce diagnostic error rates and enhance workflow efficiency for pathologists. Deployed globally, the Galen platform includes AI-based cancer detection solutions like Galen Prostate and Galen Breast, which are used in routine clinical practice. The company also focuses on developing computational prognostic and predictive tests to enable enhanced patient stratification and personalized treatment selection, serving the digital healthcare and medical decision support sectors.

Strategic signal

In February 2025, Ibex Medical Analytics appointed a new executive, a former. This signals a strategic move to strengthen leadership and accelerate growth, indicating a robust financial position and a clear intent to scale operations and market presence, particularly in the wake of substantial capital injection.

Company Intelligence Q&A

What was the most recent funding round for Ibex Medical Analytics?

In September 2023, Ibex Medical Analytics completed a Series C funding round. The round was led by 83North, with participation from Sienna Venture Capital.

What significant product was launched by Ibex Medical Analytics in September 2022?

In September 2022, Ibex Medical Analytics launched Galen 3.0, an AI-powered solution for cancer diagnosis. This platform offers new detection capabilities and features to support pathologists in diagnosing multiple tissue types.

Did Ibex Medical Analytics receive any regulatory approvals in 2022?

In June 2022, Ibex Medical Analytics received CE mark approval for its Galen gastric cancer detection solution, an AI-powered technology designed to analyze biopsy slides and detect gastric cancer.

What strategic partnership did Ibex Medical Analytics announce in March 2022?

In March 2022, Ibex Medical Analytics announced a strategic partnership with Dedalus Group to integrate Ibex's clinical-grade AI algorithms into Dedalus's end-to-end digital pathology solution, aiming to enhance diagnostic quality.

What was the outcome of the FDA Breakthrough Device Designation for Ibex Medical Analytics?

In June 2021, Ibex Medical Analytics was granted Breakthrough Device Designation by the FDA for its AI-powered cancer diagnostics platform, which is intended to expedite the clinical review and regulatory approval process for the technology.